Klaus Veitinger

Président chez Neurogastrx, Inc.

Profil

Dr. Klaus R.
Veitinger is a Chairman at Promentis Pharmaceuticals, Inc., a Venture Partner at OrbiMed Advisors Private Equity, a Chairman at Neurogastrx, Inc. and a Chairman at Sparrow Pharmaceuticals, Inc. Dr. Veitinger was previously employed as an Independent Director by scPharmaceuticals, Inc., a Chairman by Tricida, Inc., a Chairman by Symbiomix Therapeutics LLC, an Independent Director by Intercept Pharmaceuticals, Inc., a Vice Chairman by Relypsa, Inc., a President & Chief Executive Officer by Schwarz Pharma, Inc., and a Member-Management Board by Schwarz Pharma AG.
He also served on the board at Chroma Therapeutics Ltd., Biolex Therapeutics, Inc., Bone Care International, Inc., Gelesis, Inc. and Pharmaceutical Research & Manufacturers of America.
He received his MBA from INSEAD and a doctorate degree from Heidelberg University (Ohio).

Postes actifs de Klaus Veitinger

Sociétés	Poste	Début
OrbiMed Advisors Private Equity	Private Equity Investor	01/01/2007
Promentis Pharmaceuticals, Inc.	Président	01/04/2008
Neurogastrx, Inc.	Président	04/01/2018
Sparrow Pharmaceuticals, Inc.	Président	-
CranioVation, Inc.	Directeur/Membre du Conseil	-

Anciens postes connus de Klaus Veitinger

Sociétés	Poste	Fin
SCPHARMACEUTICALS INC.	Directeur/Membre du Conseil	07/10/2025
TRICIDA, INC.	Président	01/06/2023
INTERCEPT PHARMACEUTICALS, INC.	Directeur/Membre du Conseil	01/07/2016
Symbiomix Therapeutics LLC	Directeur Général	01/12/2015
░░░░░░░ ░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░